About veru inc - VERU
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. The company was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1971 and is headquartered in Miami, FL.
VERU At a Glance
Veru, Inc.
2916 North Miami Avenue
Miami, Florida 33127
| Phone | 1-305-509-6897 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -18,622,462.00 | |
| Sector | Health Technology | Employees | 20 | |
| Fiscal Year-end | 09 / 2026 | |||
| View SEC Filings |
VERU Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.037 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.143 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.077 |
VERU Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -931,123.10 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
VERU Liquidity
| Current Ratio | 2.43 |
| Quick Ratio | 2.43 |
| Cash Ratio | 2.353 |
VERU Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -34.597 |
| Return on Equity | -61.921 |
| Return on Total Capital | -73.107 |
| Return on Invested Capital | -48.414 |
VERU Capital Structure
| Total Debt to Total Equity | 17.002 |
| Total Debt to Total Capital | 14.532 |
| Total Debt to Total Assets | 10.447 |
| Long-Term Debt to Equity | 12.862 |
| Long-Term Debt to Total Capital | 10.993 |